These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30226378)

  • 1. Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.
    Bamborough P; Chung CW; Furze RC; Grandi P; Michon AM; Watson RJ; Mitchell DJ; Barnett H; Prinjha RK; Rau C; Sheppard RJ; Werner T; Demont EH
    J Med Chem; 2018 Sep; 61(18):8321-8336. PubMed ID: 30226378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach.
    Miller DC; Martin MP; Adhikari S; Brennan A; Endicott JA; Golding BT; Hardcastle IR; Heptinstall A; Hobson S; Jennings C; Molyneux L; Ng Y; Wedge SR; Noble MEM; Cano C
    Org Biomol Chem; 2018 Mar; 16(11):1843-1850. PubMed ID: 29469144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification.
    Bamborough P; Chung CW; Demont EH; Bridges AM; Craggs PD; Dixon DP; Francis P; Furze RC; Grandi P; Jones EJ; Karamshi B; Locke K; Lucas SCC; Michon AM; Mitchell DJ; Pogány P; Prinjha RK; Rau C; Roa AM; Roberts AD; Sheppard RJ; Watson RJ
    J Med Chem; 2019 Aug; 62(16):7506-7525. PubMed ID: 31398032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.
    Lucas SCC; Atkinson SJ; Bamborough P; Barnett H; Chung CW; Gordon L; Mitchell DJ; Phillipou A; Prinjha RK; Sheppard RJ; Tomkinson NCO; Watson RJ; Demont EH
    J Med Chem; 2020 May; 63(10):5212-5241. PubMed ID: 32321240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.
    Winter-Holt JJ; Bardelle C; Chiarparin E; Dale IL; Davey PRJ; Davies NL; Denz C; Fillery SM; Guérot CM; Han F; Hughes SJ; Kulkarni M; Liu Z; Milbradt A; Moss TA; Niu H; Patel J; Rabow AA; Schimpl M; Shi J; Sun D; Yang D; Guichard S
    J Med Chem; 2022 Feb; 65(4):3306-3331. PubMed ID: 35133824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
    Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
    J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
    Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
    J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATAD2 in cancer: a pharmacologically challenging but tractable target.
    Hussain M; Zhou Y; Song Y; Hameed HMA; Jiang H; Tu Y; Zhang J
    Expert Opin Ther Targets; 2018 Jan; 22(1):85-96. PubMed ID: 29148850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
    Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action.
    Fernández-Montalván AE; Berger M; Kuropka B; Koo SJ; Badock V; Weiske J; Puetter V; Holton SJ; Stöckigt D; Ter Laak A; Centrella PA; Clark MA; Dumelin CE; Sigel EA; Soutter HH; Troast DM; Zhang Y; Cuozzo JW; Keefe AD; Roche D; Rodeschini V; Chaikuad A; Díaz-Sáez L; Bennett JM; Fedorov O; Huber KVM; Hübner J; Weinmann H; Hartung IV; Gorjánácz M
    ACS Chem Biol; 2017 Nov; 12(11):2730-2736. PubMed ID: 29043777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening.
    Yao D; Zhang J; Wang J; Pan D; He Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):713-725. PubMed ID: 32174193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
    Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
    J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromodomains and their pharmacological inhibitors.
    Gallenkamp D; Gelato KA; Haendler B; Weinmann H
    ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.